A major financial boost empowers Isomorphic Labs to accelerate its pioneering work in AI-powered drug development, aiming to bridge the gap between discovery and patient care. Isomorphic Labs, an innovative platform dedicated to AI-driven drug discovery that originated from Google's DeepMind in 2021, has successfully completed a Series C funding round, amassing an impressive $5 billion. This substantial investment is intended to advance its therapeutic candidates into human clinical trials. The funding initiative saw co-leadership from prominent firms Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new investor, alongside continued support from existing backers including Alphabet's GV and Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund.
The company's innovative AI platform, rooted in Nobel Prize-winning research, has already shown significant potential in addressing critical health challenges. Isomorphic Labs develops an advanced AI engine for drug design, employing a suite of artificial intelligence simulation models to explore diverse chemical pathways and facilitate the creation of novel medicines. This work is fundamentally built upon DeepMind’s groundbreaking AlphaFold protein-folding AI model, which earned its creators the Nobel Prize in chemistry for predicting protein 3D structures from genetic sequences. The company has announced positive preclinical results in key medical fields such as oncology and immunology, and has forged strategic collaborations with major pharmaceutical entities, including Eli Lilly, Novartis, and Johnson & Johnson. This recent capital infusion follows a $2.1 billion Series B round in May and will be allocated to further enhance its drug-design engine and venture into additional medical specializations.
Under the guidance of its visionary founder, Isomorphic Labs is strategically positioned to redefine the future of pharmaceutical innovation. This Series C represents the company’s first major fundraising since its founder and CEO, Demis Hassabis, transitioned from his leadership role at DeepMind to dedicate himself fully to drug discovery, also assuming the chairman position at DeepMind. Although Isomorphic Labs has not disclosed its updated valuation, reports indicated earlier this month that the lab was seeking funding based on an estimated valuation of $50 billion.
The successful funding achievement of Isomorphic Labs signifies a pivotal moment in healthcare innovation. By leveraging advanced artificial intelligence and substantial financial backing, the company is not only accelerating the development of new treatments but also fostering a future where complex diseases might be addressed with unprecedented precision and efficiency. This progress holds the promise of transforming patient outcomes globally and underscores the profound positive impact that cutting-edge technology can have when applied to critical scientific endeavors.
Isomorphic Labs, a pioneering AI drug-discovery platform born from Google's DeepMind, has successfully concluded a Series C funding round, raising a remarkable $5 billion. This significant financial injection is earmarked for propelling its AI-designed drug candidates into crucial clinical trials. Utilizing sophisticated simulation AI models, building upon the Nobel Prize-winning AlphaFold technology, the company has already reported encouraging preclinical results in crucial areas like oncology and immunology. With strategic alliances established with leading pharmaceutical corporations, Isomorphic Labs is positioned to revolutionize the creation of new therapeutic solutions.
Following Nvidia CEO Jensen Huang's unexpected resignation, Hugging Face CEO Clément Delangue affirmed his company's unwavering commitment to advancing open-source AI. Huang's departure has sparked discussions about the future of open-source initiatives within Nvidia, especially concerning its $12.9 billion acquisition of Hugging Face. Delangue's statement aims to reassure the AI community about the platform's dedication to its core principles amidst these significant industry shifts.
SoftBank incurred a significant financial setback exceeding $3 billion due to its aggressive pre-ordering of natural gas turbines, intended to power AI data centers. This decision, driven by the rapid increase in AI's energy consumption, reflects a broader industry challenge in securing adequate power infrastructure. The unexpected loss highlights the volatile nature of energy markets and the complexities in forecasting technological demands, prompting a reevaluation of energy supply strategies for AI development.
United Airlines has announced it will prohibit artificial intelligence agents and autonomous assistants from booking flights and managing reservations for users. The airline cites significant cybersecurity risks and potential violations of federal regulations as primary reasons for this decision. This move aligns with a growing trend among major corporations, including financial institutions, to address the security implications of customers sharing login credentials with AI tools, which could lead to data breaches or unintended account activities.
Norwest, a venerable multi-stage investment firm exclusively backed by Wells Fargo, has successfully closed its eighteenth and largest fund to date, amassing $4 billion. This new capital infusion is earmarked for strategic investments across the United States, India, and Israel, with a significant emphasis on artificial intelligence. The firm aims to bolster its portfolio with innovative AI startups spanning consumer, healthcare, and technology sectors, including physical AI, voice AI, agentic cybersecurity, and aerospace.
Following Jensen Huang's resignation as Nvidia CEO, former U.S. President Donald Trump has publicly proposed that Tim Cook, former CEO and current Executive Chairman of Apple, is the only suitable candidate to fill the vacant leadership role. This suggestion, shared on Truth Social, aligns with opinions from some corporate governance experts, highlighting Cook's proven track record of successful leadership transitions.